{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:06:09Z","timestamp":1792497969216,"version":"4.5.0"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Long term benefits following short-term administration of high psychedelic doses of serotonergic and dissociative hallucinogens, typified by psilocybin and ketamine respectively, support their potential as treatments for psychiatric conditions such as major depressive disorder. The high psychedelic doses induce perceptual experiences which are associated with therapeutic benefit. There have also been anecdotal reports of these drugs being used at what are colloquially referred to as \u201cmicro\u201d doses to improve mood and cognitive function, although currently there are recognized limitations to their clinical and preclinical investigation. In the present studies we have defined a low dose and plasma exposure range in rats for both ketamine (0.3\u20133\u00a0mg\/kg [10\u201373\u00a0ng\/ml]) and psilocybin\/psilocin (0.05\u20130.1\u00a0mg\/kg [7\u201312\u00a0ng\/ml]), based on studies which identified these as sub-threshold for the induction of behavioral stereotypies. Tests of efficacy were focused on depression-related endophenotypes of anhedonia, amotivation and cognitive dysfunction using low performing male Long Evans rats trained in two food motivated tasks: a progressive ratio (PR) and serial 5-choice (5-CSRT) task. Both acute doses of ketamine (1\u20133\u00a0mg\/kg IP) and psilocybin (0.05\u20130.1\u00a0mg\/kg SC) pretreatment increased break point for food (PR task), and improved attentional accuracy and a measure of impulsive action (5-CSRT task). In each case, effect size was modest and largely restricted to test subjects characterized as \u201clow performing\u201d. Furthermore, both drugs showed a similar pattern of effect across both tests. The present studies provide a framework for the future study of ketamine and psilocybin at low doses and plasma exposures, and help to establish the use of these lower concentrations of serotonergic and dissociative hallucinogens both as a valid scientific construct, and as having a therapeutic utility.<\/jats:p>","DOI":"10.3389\/fphar.2021.640241","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T07:22:21Z","timestamp":1614324141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":66,"title":["Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property"],"prefix":"10.3389","volume":"12","author":[{"given":"Guy A.","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole K.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cam","family":"MacMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo B.","family":"Silenieks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Thevarkunnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Izhakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Magomedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"DeLannoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"B2","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","year":"2013"},{"key":"B104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2019.05.013","article-title":"Cognitive dysfunction in major depression: From assessment to novel therapies","volume":"202","author":"Atique-Ur-Rehman","year":"2019","journal-title":"Pharmacol. Ther"},{"key":"B103","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00213-018-4836-5","article-title":"Differences in trait impulsivity do not bias the response to pharmacological drug challenge in the rat five-choice serial reaction time task","volume":"235","author":"Barlow","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e115374","DOI":"10.1371\/journal.pone.0115374","article-title":"Investigating glutamatergic mechanism in attention and impulse control using rats in a modified 5-choice serial reaction time task","volume":"9","author":"Benn","year":"2014","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00008877-200503000-00004","article-title":"Evaluation of DOI, 8-OH-DPAT, eticlopride and amphetamine on impulsive responding in a reaction time task in rats","volume":"16","author":"Blokland","year":"2005","journal-title":"Behav. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.biopsych.2006.06.030","article-title":"Dimensional analysis of ADHD subtypes in rats","volume":"61","author":"Blondeau","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","article-title":"The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity","volume":"95","author":"Bortolozzi","year":"2005","journal-title":"J. Neurochem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fpsyg.2012.00153","article-title":"Impulsivity and rapid decision-making for reward","volume":"3","author":"Burnett Heyes","year":"2012","journal-title":"Front. Psychol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, intermittent microdoses of the psychedelic N, N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1176\/appi.focus.16407","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/DDDT.S221437","article-title":"Ketamine and depression: a narrative review","volume":"13","author":"Corriger","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B14","first-page":"696","article-title":"Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic","volume":"9","author":"Day","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.pneurobio.2016.03.004","article-title":"Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications","volume":"151","author":"De Deurwaerd\u00e8re","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/7854_2015_5004","article-title":"Translational assessment of reward and motivational deficits in psychiatric disorders","volume":"28","author":"Der-Avakian","year":"2016","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1037\/\/0022-3514.58.1.95","article-title":"Functional and dysfunctional impulsivity: personality and cognitive correlates","volume":"58","author":"Dickman","year":"1990","journal-title":"J. Pers Soc. Psychol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s0006-8993(00)02062-x","article-title":"Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area","volume":"864","author":"Doherty","year":"2000","journal-title":"Brain Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1472-8206.2004.00292.x","article-title":"Impact of inter\u2010individual differences in drug metabolism and pharmacokinetics on safety evaluation","volume":"18","author":"Dorne","year":"2004","journal-title":"Fundam. Clin. Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s0896-6273(00)00112-4","article-title":"Major depressive disorder","volume":"28","author":"Fava","year":"2000","journal-title":"Neuron"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/npp.2015.46","article-title":"Individual differences in impulsive action reflect variation in the cortical serotonin 5-HT2A receptor system","volume":"40","author":"Fink","year":"2015","journal-title":"Neuropsychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1038\/sj.mp.4001015","article-title":"Delayed pharmacological effects of antidepressants","volume":"7","author":"Frazer","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e014912","DOI":"10.1136\/bmjopen-2016-014912","article-title":"Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews","volume":"7","author":"Gartlehner","year":"2017","journal-title":"BMJ Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.euroneuro.2013.03.002","article-title":"Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat","volume":"23","author":"Gastambide","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1021\/acschemneuro.8b00186","article-title":"DARK classics in chemical neuroscience: psilocybin","volume":"9","author":"Geiger","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.addbeh.2014.04.022","article-title":"Impulsive action and impulsive choice across substance and behavioral addictions: cause or consequence?","volume":"39","author":"Grant","year":"2004","journal-title":"Addict. Behav."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nlm.2015.07.015","article-title":"Contribution of N-methyl-D-aspartate receptors to attention and episodic spatial memory during senescence","volume":"125","author":"Guidi","year":"2015","journal-title":"Neurobiol. Learn. Mem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbr.2013.08.045","article-title":"Animal models of the serotonin syndrome: a systematic review","volume":"256","author":"Haberzettl","year":"2013","journal-title":"Behav. Brain Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/7854_2016_466","article-title":"Effect of hallucinogens on unconditioned behavior","volume":"36","author":"Halberstadt","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1021\/cn300138m","article-title":"Animal models of serotonergic psychedelics","volume":"4","author":"Hanks","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.npp.1300506","article-title":"Discovering endophenotypes for major depression","volume":"29","author":"Hasler","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.11.010","article-title":"Low attentive and high impulsive rats: a translational animal model of ADHD and disorders of attention and impulse control","volume":"158","author":"Hayward","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00213-005-2203-9","article-title":"Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat","volume":"179","author":"Higgins","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"108064","DOI":"10.1016\/j.neuropharm.2020.108064","article-title":"Effects of 5-HT 2C receptor modulation and the NA reuptake inhibitor atomoxetine in tests of compulsive and impulsive behaviour","volume":"170","author":"Higgins","year":"","journal-title":"Neuropharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00213-003-1549-0","article-title":"The 5-HT2A receptor antagonist M100,907 attenuates motor and \u201cimpulsive-type\u201d behaviours produced by NMDA receptor antagonism","volume":"170","author":"Higgins","year":"2003","journal-title":"Psychopharmacology"},{"key":"B105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2016.05.025","article-title":"Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment","volume":"311","author":"Higgins","year":"2016","journal-title":"Behav. Brain Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fphar.2020.00427","article-title":"Characterization of amphetamine, methylphenidate, nicotine, and atomoxetine on measures of attention, impulsive action, and motivation in the rat: implications for translational research","volume":"11","author":"Higgins","year":"","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpph.27","article-title":"Rodent test of attention and impulsivity: the 5-choice serial reaction time task","volume":"78","author":"Higgins","year":"2017","journal-title":"Curr. Protoc. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/FBP.0000000000000394","article-title":"Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats","volume":"29","author":"Horsley","year":"2018","journal-title":"Behav. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1073\/pnas.0308455101","article-title":"NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex","volume":"101","author":"Jackson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1455072517753339","article-title":"Powerful substances in tiny amounts: an interview study of psychedelic microdosing","volume":"35","author":"Johnstad","year":"2018","journal-title":"Nord. Stud. Alcohol. Dr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1242\/dmm.010934","article-title":"Highly impulsive rats: modelling an endophenotype to determine the neurobiological, genetic and environmental mechanisms of addiction","volume":"6","author":"Jupp","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"B48","first-page":"968","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"CANMAT depression work GroupCanadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and metabotropic glutamate receptor structure and pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/s0028-3908(99)00159-8","article-title":"Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task","volume":"39","author":"Koskinen","year":"2000","journal-title":"Neuropharmacology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0361-9230(00)00425-1","article-title":"Studies on the involvement of the dopaminergic system in the 5-HT2 agonist (DOI)-induced premature responding in a five-choice serial reaction time task","volume":"54","author":"Koskinen","year":"2001","journal-title":"Brain Res. Bull."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2045125320950567","DOI":"10.1177\/2045125320950567","article-title":"The therapeutic potential of microdosing psychedelics in depression","volume":"10","author":"Kuypers","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00003088-199834040-00005","article-title":"Predicting effective drug concentrations for individual patients","volume":"34","author":"Levy","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1111\/bph.13222","article-title":"Ketamine and phencyclidine: the good, the bad and the unexpected","volume":"172","author":"Lodge","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00823-4","article-title":"Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin","author":"Madsen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: the future path for animal models","volume":"34","author":"Markou","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2165\/11633130-000000000-00000","article-title":"Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date","volume":"72","author":"Mathews","year":"2012","journal-title":"Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1021\/acschemneuro.5b00023","article-title":"Cartography of 5-HT1A and 5-HT2A receptor subtypes in prefrontal cortex and its projections","volume":"6","author":"Mengod","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00249896","article-title":"NMDA receptor antagonists can enhance or impair learning performance in animals","volume":"75","author":"Mondadori","year":"1989","journal-title":"Exp. Brain Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00213-018-4828-5","article-title":"Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study","volume":"235","author":"Morrison","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e2001307","DOI":"10.1371\/journal.pbio.2001307","article-title":"Increasing efficiency of preclinical research by group sequential designs","volume":"15","author":"Neumann","year":"2017","journal-title":"PLos Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"Nichols","year":"2016","journal-title":"Psychedelics. Pharmacol. Rev."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.euroneuro.2014.04.007","article-title":"The effects of acute and repeated administration of ketamine on attentional performance in the five-choice serial reaction time task in rats","volume":"24","author":"Nikiforuk","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0306-4522(01)00593-0","article-title":"Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group","volume":"111","author":"Nocjar","year":"2002","journal-title":"Neuroscience"},{"key":"B71","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881106069938","article-title":"The other face of depression, reduced positive affect: the role of catecholamines in causation and cure","volume":"21","author":"Nutt","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"B72","doi-asserted-by":"crossref","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs-a new era in psychiatry?","volume":"21","author":"Nutt","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e0211023","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"key":"B74","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu017","article-title":"Bupropion increases selection of high effort activity in rats tested on a progressive ratio\/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms","volume":"18","author":"Randall","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e47934","DOI":"10.1371\/journal.pone.0047934","article-title":"Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences","volume":"7","author":"Randall","year":"2012","journal-title":"PLoS One"},{"key":"B77","first-page":"275","article-title":"Understanding antipsychotic \u201catypicality\u201d: a clinical and pharmacological moving target","volume":"28","author":"Remington","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00213-002-1154-7","article-title":"The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry","volume":"163","author":"Robbins","year":"2002","journal-title":"Psychopharmacology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/(SICI)1097-4547(20000415)60:2<202::AID-JNR9>3.0.CO;2-J","article-title":"N-methyl-D-aspartate (NMDA) receptors in the ventral tegmental area: subcellular distribution and colocalization with 5-hydroxytryptamine(2A) receptors","volume":"60","author":"Rodr\u00edguez","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"B80","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1096-9861(19991018)413:2<219::AID-CNE4>3.0.CO;2-F","article-title":"Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum","volume":"413","author":"Rodr\u00edguez","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/0269881120908004","article-title":"Microdosing psychedelics: demographics, practices, and psychiatric comorbidities","volume":"34","author":"Rosenbaum","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2042098620937899","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"Salahudeen","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"B85","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neubiorev.2010.06.006","article-title":"Reconsidering anhedonia in depression: lessons from translational neuroscience","volume":"35","author":"Treadway","year":"2011","journal-title":"Neurosci. Biobehav Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0014-2999(89)90754-1","article-title":"The behavioural effects of MK801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor","volume":"167","author":"Tricklebank","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin-summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1741-7015-10-156","article-title":"Data-driven subtypes of major depressive disorder: a systematic review","volume":"10","author":"Van Loo","year":"2012","journal-title":"BMC Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0893-133X(98)00072-4","article-title":"M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats","volume":"20","author":"Varty","year":"1999","journal-title":"Neuropsychopharmacol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0014-2999(95)00660-5","article-title":"Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin","volume":"287","author":"Varty","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues Clin. Neurosci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"B96","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0893-133X(98)00003-7","article-title":"M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice","volume":"19","author":"Wang","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0165-6147(90)90150-7","article-title":"The behavioral pharmacology of NMDA receptor antagonists","volume":"11","author":"Willetts","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00213-011-2441-y","article-title":"Pre-treatment with the mGlu2\/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression","volume":"219","author":"Wischhof","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.1073\/pnas.83.18.7104","article-title":"The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist","volume":"83","author":"Wong","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv124","article-title":"Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis","volume":"19","author":"Xu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B101","first-page":"59","article-title":"The place of dysfunctional and functional impulsivity in the personality structure","volume":"14","author":"Zadravec","year":"2005","journal-title":"Horizons Psychol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.640241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T07:22:31Z","timestamp":1614324151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.640241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":105,"alternative-id":["10.3389\/fphar.2021.640241"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.640241","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"article-number":"640241"}}